© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 3, 264-270,
February 3, 1999
© 1999 Oxford University Press
REPORTS |
Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study
Affiliations of authors: C. Schairer, S. R. Sturgeon, L. A. Brinton, R. N. Hoover (Environmental Epidemiology Branch), M. Gail, P. S. Rosenberg (Biostatistics Branch), Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; C. Byrne, Channing Laboratory, Harvard Medical School, Boston, MA.
Correspondence to: Catherine Schairer, Ph.D., National Institutes of Health, EPN, Rm. 443, 6130 Executive Blvd., MSC 7374, Bethesda, MD 20892-7374 (e-mail: Schairec{at}epndce.nci.nih.gov).
BACKGROUND: Hormone replacement therapy has been associated in some studies with reductions in breast cancer mortality among women who develop this disease. It is unclear whether this association reflects the biologic activity of the hormones or the earlier detection of tumors among hormone users. We examined breast cancer mortality among women who were diagnosed with axillary lymph node-negative and node-positive breast cancer according to the currency of estrogen use at diagnosis. METHODS: Vital status through June 1995 was determined for 2614 patients with postmenopausal breast cancer diagnosed during the period from 1973 to January 1981. We estimated adjusted hazard-rate ratios (adjusting for tumor size, age, race, Quetelet [body mass] index, and number of positive lymph nodes in women with node-positive disease) and unadjusted cumulative probabilities of breast cancer death over time since diagnosis. RESULTS: Among patients with node-negative disease, rate ratios for breast cancer mortality associated with current use compared with nonuse at diagnosis were 0.5 (95% confidence interval [CI] = 0.3-0.8) until 144 months after diagnosis and 2.2 (95% CI = 0.9-5.2) thereafter. Mortality was not statistically significantly lower in past users. The cumulative probabilities of breast cancer mortality at the end of follow-up were 0.14, 0.14, and 0.09 in nonusers, past users, and current users, respectively. Among women with node-positive disease, the rate ratios associated with current and past use were both 0.5 until 48 months after diagnosis (95% CI = 0.3-0.8 for current users; 95% CI = 0.3-0.9 for past users) and were 1.1 (95% CI = 0.7-1.7) and 1.8 (95% CI = 1.2-2.7), respectively, thereafter. The cumulative probabilities of breast cancer mortality were 0.32, 0.39, and 0.27 in nonusers, past users, and current users, respectively. CONCLUSIONS: Patients with breast cancer who were using replacement estrogens at the time of diagnosis experienced reductions in breast cancer mortality, which waned with the time since diagnosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Brewster, K.-A. Do, P. A. Thompson, K. M. Hahn, A. A. Sahin, Y. Cao, M. M. Stewart, J. L. Murray, G. N. Hortobagyi, and M. L. Bondy Relationship Between Epidemiologic Risk Factors and Breast Cancer Recurrence J. Clin. Oncol., October 1, 2007; 25(28): 4438 - 4444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Punchihewa, A. De Alba, N. Sidell, and D. Yang XR5944: A potent inhibitor of estrogen receptors Mol. Cancer Ther., January 1, 2007; 6(1): 213 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stahlberg, E. Lynge, Z. J. Andersen, N. Keiding, B. Ottesen, F. Rank, Y. A. Hundrup, E. B Obel, and A. T. Pedersen Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy--a prospective observational study Int. J. Epidemiol., August 1, 2005; 34(4): 931 - 935. [Full Text] [PDF]
|
|
|
|
 |
|
 ESHRE Capri Workshop Group Hormones and breast cancer Hum. Reprod. Update, July 1, 2004; 10(4): 281 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoine, F. Liebens, B. Carly, A. Pastijn, and S. Rozenberg Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial Hum. Reprod., March 1, 2004; 19(3): 741 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. VASSILOPOULOU-SELLIN Breast Cancer and Hormonal Replacement Therapy Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Daling, K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, P. A. Marchbanks, R. J. Coates, S. A. Norman, L. K. Weiss, G. Ursin, et al. Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1175 - 1181. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial JAMA, June 25, 2003; 289(24): 3243 - 3253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Levy, J. M. Ritchie, E. Smith, T. Gray, and W. Zhang Physician Specialty Is Significantly Associated With Hormone Replacement Therapy Use Obstet. Gynecol., January 1, 2003; 101(1): 114 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan Postmenopausal Hormone Replacement Therapy: Scientific Review JAMA, August 21, 2002; 288(7): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Vogel Why Do We Still Use Hormone Replacement Therapy? Why Don't We Use It More? J. Clin. Oncol., February 1, 2002; 20(3): 616 - 619. [Full Text] [PDF]
|
|
|
|
|
|
A. GUERRIERI-GONZAGA, A. GALLI, N. ROTMENSZ, and A. DECENSI The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and New Perspectives Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Bush, M. Whiteman, and J. A. Flaws Hormone Replacement Therapy and Breast Cancer: A Qualitative Review Obstet. Gynecol., September 1, 2001; 98(3): 498 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cuzick Is Hormone Replacement Therapy Safe for Breast Cancer Patients? J Natl Cancer Inst, May 16, 2001; 93(10): 733 - 733. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Santen, J. Pinkerton, C. McCartney, and G. R. Petroni Risk of Breast Cancer with Progestins in Combination with Estrogen as Hormone Replacement Therapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 16 - 23. [Full Text]
|
|
|
|
|
|
L. A. Bazzano, G. Del Priore, M.-J. Lee, A. N. Glaser, J. A. Harvey, C. J. Newschaffer, K. J. Helzlsouer, C. A. Roca, P. J. Schmidt, R. C. Daly, et al. Estrogen-Progestin Replacement and Risk of Breast Cancer JAMA, August 9, 2000; 284(6): 691 - 694. [Full Text] [PDF]
|
|
|
|
|
|
C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk JAMA, January 26, 2000; 283(4): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Bush and M. K. Whiteman Hormone Replacement Therapy and Risk of Breast Cancer JAMA, June 9, 1999; 281(22): 2140 - 2141. [Full Text] [PDF]
|
|